Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must have a non-resectable cancer of head and neck~* must have a pathologically proven squamous cell carcinoma arising in the oropharynx, oral cavity, hypopharynx, or larynx or cancer of unknown primary site~* must have a stage III or IV disease with an expected survival time of ≥ 12 months with node status of N0-N2~* must be medically suitable to withstand a course of definitive radiation therapy and concomitant chemotherapy or antibody-therapy~* must have a Karnofsky performance status (KPS) of ≥ 70 at the time of screening~* must be between ≥18 and ≤80 years of age~* must have the following laboratory values:~Analysis/International System of Units (SI units) Neutrophil count/≥ 1.5 G/l Platelet count/≥ 100 G/l Serum glutamate oxaloacetate transaminase (SGOT)/≤ 2 x the upper limit of normal Serum glutamate pyruvate transaminase (SGPT)/≤ 2 x the upper limit of normal Serum creatinine or estimated creatinine clearance/≤ 1.5mg/dl or Epidermal growth factor receptor (eGFR)≥ 50 ml/min/1.73m² Serum calcium/Within normal limits~* must be disease free from a previously treated malignancy for more than three years~* must provide a signed and dated written informed consent~* Female subject of childbearing potential must:~  * Understand that the study medication could have an expected teratogenic risk~ * Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 3 months after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception\* Implant Levonorgestrel-releasing intrauterine system (IUS) Medroxyprogesterone acetate depot Tubal sterilisation Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses Ovulation inhibitory progesterone-only pills (i.e., desogestrel)~    \* Combined oral contraceptive pills are not recommended. If a subject was using combined oral contraception, she must switch to one of the methods above. The increased risk of venous thromboembolism (VTE) continues for 4 to 6 weeks after stopping combined oral contraception.~ * Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 milli-International units (mIU)/ml not more than 3 days before the start of study medication once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.~ * Agree to have a medically supervised pregnancy test every 4 weeks including 3 months after the end of study treatment, except in the case of confirmed tubal sterilization. These tests should be performed not more than 3 days before the start of next treatment. This requirement also applies to women of childbearing potential who practice complete and continued abstinence~* Male subject must:~  * Agree to use condoms throughout study drug therapy, during any dose interruption and for up to 3 months after cessation of study therapy if his partner is of childbearing potential and has no contraception.~ * Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.~Exclusion Criteria:~* Evidence of distant metastatic disease~* Prior systemic chemotherapy within the last three years~* Previous surgery for the tumor under study, other than biopsy and debulking of squamous cell carcinoma arising in the larynx~* Prior radiation therapy to the head and neck~* Receiving radiation therapy as part of a postoperative regimen following primary surgical resection~* Pregnancy or breastfeeding~* Patient received prior Cetuximab or murine monoclonal antibody therapy~* Patient received prior Mitomycin-C and 5-Fluorouracil~* Actual hemorrhages~* Stomatitis, ulcerations in the mouth and the gastrointestinal tract~* Actual severe diarrhea~* Severe infectious diseases (Hepatitis A, B, C, D HIV)~* Coagulation disorders~* Active vaccination~* Patient has a medical or psychological condition that would not permit the patient to complete the trial or sign the informed consent~* Active participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: ACTIVE_COMPARATOR): Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
- Mitomycin-C / 5-Fluorouracil (Type: ACTIVE_COMPARATOR): Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).